SCHEMBL25215228

SCHEMBL25215228

C#Cc1ccc2c(c1)C(=O)NC2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 3/20 0.51
NTRK2 Q16620 2/20 0.51
DYRK1B Q9Y463 2/20 0.51
TYRO3 Q06418 1/20 0.51
NTRK1 P04629 2/20 0.50
FLT3 P36888 2/20 0.50
GSK3B P49841 2/20 0.50
JAK2 O60674 1/20 0.50
MET P08581 1/20 0.50
FGFR1 P11362 1/20 0.50
PRKACA P17612 1/20 0.50
KDR P35968 1/20 0.50
MAP2K2 P36507 1/20 0.50
MAP2K1 Q02750 1/20 0.50
MST1R Q04912 1/20 0.50
NTRK3 Q16288 1/20 0.50
CAMK1D Q8IU85 1/20 0.50
CA12 O43570 1/20 0.48
CA9 Q16790 1/20 0.48
GRM5 P41594 5/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29908235 0.86 GRM5 (0.64) CLK4NTRK2DYRK1BTYRO3NTRK1
SCHEMBL2041218 0.82 NTRK2 (0.51) CLK4NTRK2DYRK1BTYRO3NTRK1
SCHEMBL29948230 0.82 NTRK2 (0.51) CLK4NTRK2DYRK1BTYRO3NTRK1
SCHEMBL4728829 0.73 GRM5 (0.47) CLK4NTRK2DYRK1BTYRO3NTRK1
SCHEMBL1438328 0.73 TDP2 (0.59) CLK4NTRK2DYRK1BTYRO3NTRK1
SCHEMBL30765133 0.73 TDP2 (0.59) CLK4NTRK2DYRK1BTYRO3NTRK1
SCHEMBL17082844 0.72 CLK4 (0.56) CLK4NTRK2DYRK1BTYRO3NTRK1
SCHEMBL21267639 0.72 CLK4 (0.56) CLK4NTRK2DYRK1BTYRO3NTRK1
SCHEMBL1760377 0.72 NTRK2 (0.74) CLK4NTRK2DYRK1BTYRO3NTRK1
SCHEMBL1233219 0.72 NTRK2 (0.56) CLK4NTRK2DYRK1BTYRO3NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116157398-B Oxadiazole-based selective histone deacetylase 6 inhibitors 意大发马克股份公司 2025-03-11 CN disclosed
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS ITALFARMACO SPA (IT) 2023-09-14 US disclosed
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS ITALFARMACO SPA (IT) 2023-09-14 US disclosed
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS ITALFARMACO SPA (IT) 2023-09-14 US disclosed
EP-4192830-A1 2-(4-((5-(BENZO[B]THIOPHEN-3-YL)-1H-TETRAZOL-1-YL)METHYL)PHENYL)-5-(DIFLUOROMETHYL)-1,3,4-OXADIAZOLE DERIVATIVES AND SIMILAR COMPOUNDS AS SELECTIVE INHIBITORS OF HISTONE DEACETYLASE 6 (HDAC6) FOR USE IN TREATING E.G. PERIPHERAL NEUROPATHY Italfarmaco SpA (IT) 2023-06-14 EP disclosed
CN-116157398-A 2- (4- ((5- (benzo [ b ] thiophen-3-yl) -1H-tetrazol-1-yl) methyl) phenyl) -5- (difluoromethyl) -1,3, 4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC 6) for the treatment of, for example, peripheral neuropathy 意大发马克股份公司 2023-05-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS HDAC6, HDAC1, HDAC3 CLK4 2409/4885NTRK2 2514/4885DYRK1B 2352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.